In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 4, 2005, Pages 276-279

  Blacky, A ^a   Makristathis, A ^a   Apfalter, P ^a   Willinger, B ^a   Rotter, M L ^a   Hirschl, A M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; FOSFOMYCIN; METRONIDAZOLE;

ARTICLE; BACTERIAL STRAIN; CALCULATION; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; HELICOBACTER PYLORI; IN VITRO STUDY; INHIBITION KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TECHNIQUE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FOSFOMYCIN; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 20044372735     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-1307-9     Document Type: Article

References (13)

1. Megraud F (2001) Resistance of Helicobacter pylori to antibiotics and its impact on treatment options. Drug Resistance Updates 4:178-186
2. Philipp W, Kofler J (1986) Untersuchung des Penetrationsvermögens von Fosfomycin in das Kammerwasser und den Glaskörper des Auges. Klinische Monatsblätter für Augenheilkunde 189:240-242
3. Haag R, Hölzlberger R, Rienhoff E, Bartels F, Meissner A (1989) Experimentelle Untersuchungen und Überlegungen zur Verteilung und verzögerten Freisetzung von Fosfomycin aus Knochengewebe. ZAC Zeitschrift für antimikrobielle antineoplastische Chemotherapie 7:3-10
4. Frossard M, Joukhadar C, Erovic BM, Dittrich P, Mrass PE, van Houte M, et al (2000) Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 44:2728-2732
5. Drugeon H, Baron D, Chung Courtieu A (1980) The resistance to fosfomycin by mutation. A study in vitro. Clinical consequences. Drugs Exp Clin Res 6:345-349
6. National Committee for Clinical Laboratory Standards (2000) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th edn. Approved Standard M7-A5. NCCLS, Villanova, PA, USA
7. Hirschl AM, Apfalter P, Makristathis A, Rotter M, Wimmer M (2000) In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 44:1977-1979
8. Moody JA (1991) Synergism testing. Broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD (ed) Clinical microbiology procedures handbook. Vol. 1.1. American Society for Microbiology, Washington, D.C., USA. pp.5.18.1-5.18.28
9. Andrews JM, Baquero F, Beltran JM, Canton E, Crokaert F, Gobernado M, et al (1983) International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 12:357-361
10. Gallego A, Rodriguez A, Mata M (1974) Fosfomycin: pharmacological studies. Drugs of Today 10(Suppl 11):161-168
11. Lind T, Mégraud F, Unge P, et al (1999) The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253
12. Malfertheiner P, Mégraud F, O'Morain C, et al and the European Helicobacter pylori Study Group (2002) Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180
13. Bazzoli F, Pozzato P, Rokkast T (2002) Helicobacter pylori: the challenge in therapy. Helicobacter 7(Suppl1):43-49